DSIP Spray 5 mg

One-Peptides DSIP 5 mg — Delta Sleep-Inducing Peptide nasal spray for laboratory research

This product is a reagent intended solely for scientific research (Research Use Only, RUO) conducted under laboratory conditions. It is not a medicinal product, dietary supplement, cosmetic or medical device. It is not intended for consumption, or for administration to humans or animals outside a strictly controlled, legally compliant research protocol. The material holds no authorisation for diagnostic or therapeutic applications. Responsibility for the compliant storage, handling and use of the reagent rests with the research facility.

DSIP, or Delta Sleep-Inducing Peptide, is one of the more enigmatic neuroactive peptides that neuroscience has encountered. Its history begins in the 1970s, when Swiss researchers isolated the molecule from the blood of rabbits in deep slow-wave sleep. The name it was given still raises more questions than answers — because although it suggests a simple function of “inducing delta sleep”, the actual role of DSIP in the organism remains the subject of ongoing scientific debate.

One-Peptides offers DSIP as a pre-dissolved solution in a nasal spray, containing 5 mg, as a research material whose purity is confirmed by HPLC. This format was developed for research teams analysing the physicochemical properties of the peptide and those interested in the intranasal route of administration in the context of small-molecule transport along the nose–brain axis. Below we present an honest picture, grounded in the available literature, of what is known about DSIP — and what we still do not know.

Delta Sleep-Inducing Peptide (DSIP) is a neuromodulatory nonapeptide composed of nine amino acid residues with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE) and a molecular mass of approximately 848 Da. It was originally isolated from the blood of rabbits in the slow-wave sleep phase. In the literature it is studied as a potential factor modulating sleep, the HPA stress axis and neuromodulatory processes, although its mechanism of action remains poorly understood.

What DSIP is — sequence and class

Delta Sleep-Inducing Peptide belongs to the group of endogenous regulatory peptides of the central nervous system. The discovery was made by Marcel Monnier and Guido Schoenenberger together with their collaborators, who perfused the brains of rabbits with venous blood drawn from animals in which slow-wave sleep had been induced by electrical stimulation of the thalamus. The peptide fraction isolated from this blood was reported to induce the characteristic delta waves in the EEG — hence the name of the molecule.

What makes DSIP so interesting for science is the dissonance between its suggestive name and its uncertain functional status. Despite decades of research, it has not been possible to establish unambiguously whether this peptide acts as a neurotransmitter, a neuromodulator or a hormone with broader action. It occurs in many tissues outside the brain, and its concentrations fluctuate with a circadian rhythm, which further complicates interpretation. For this reason DSIP is sometimes described as a “peptide in search of a function”.

Chemical characterisation

The WAGGDASGE sequence is relatively short and rich in glycine and acidic residues (aspartate, glutamate), which influences the solubility of the peptide in an aqueous environment. Its small molecular mass, around 848 Da, places DSIP within the group of small peptides — a feature of importance from the perspective of research into transport across biological barriers.

Mechanism of action in research

The mechanism of action of DSIP is among the least well explained of the known neuroactive peptides. Importantly, no receptor with which this peptide would specifically interact has been unambiguously identified to date. This gap constitutes a central problem in the interpretation of experimental data — without a known molecular target it is difficult to distinguish specific effects from non-specific ones.

1. In the area of slow-wave sleep regulation, studies conducted in animal models analysed the effect of DSIP on sleep architecture and the EEG recording. Some early work suggested an increase in the proportion of slow waves, yet these results often proved difficult to reproduce, and subsequent studies produced inconclusive findings. The literature emphasises that the data are inconsistent and do not allow unambiguous conclusions to be drawn about the role of the peptide in sleep physiology.
2. A second direction of research is the modulation of the hypothalamic-pituitary-adrenal (HPA) axis. In animal models, the effect of DSIP on responses associated with the stress axis and on hormonal parameters has been analysed. Some preclinical work described action characterised as anti-stress or as stabilising responses to stress stimuli, yet here too the picture remains incomplete and calls for cautious interpretation.
3. A third area is neuromodulation in the broad sense. The potential involvement of DSIP in processes related to circadian rhythmicity, thermoregulation and the response of neurons to various stimuli has been investigated. Taken together, the research suggests that this peptide may act on many systems, but without an identified molecular mechanism these remain observations that require further verification.

Nasal spray format — research context

Intranasal administration has for years been examined as a route that may facilitate the transport of selected molecules to the central nervous system, bypassing some of the barriers that limit systemic distribution. This mechanism, described as the nose–brain axis, is associated with the anatomical proximity of the olfactory epithelium and CNS structures, and with transport along the pathways of the olfactory and trigeminal nerves.

DSIP is a small peptide with central action, which makes it an interesting subject for research into intranasal administration — its small molecular mass is here a feature favourable to transport analyses. For this reason the nasal spray format was developed as a tool for research into the intranasal route, and not as a finished preparation with an established action profile.

It must, however, be stated honestly that clinical data on the intranasal administration of DSIP are limited, and most of the available observations come from preclinical studies. Claims about the efficacy of nose–brain transport for this particular molecule should be treated as research hypotheses, not established facts. This format therefore serves research into intranasal administration, drawing on preclinical data and physicochemical reasoning, rather than on a confirmed clinical precedent.

Applications in scientific research

DSIP in a nasal spray finds application in several areas of laboratory work, always within controlled research protocols conducted in in vitro and animal models.

• In research on sleep and EEG recording, the peptide is used as a reference material in the analysis of sleep architecture in animal models, including the assessment of the proportion of slow-wave phases and of circadian rhythmicity parameters. Given the ambiguity of earlier findings, work of this kind often focuses on attempts at replication and on the standardisation of methodology.
• In the context of the stress axis, DSIP is sometimes the subject of research into responses associated with HPA-axis activity and into markers of the stress response in preclinical models. These analyses encompass both behavioural and biochemical parameters.
• In the area of neuromodulation, the peptide serves as a tool for investigating interactions at the level of the central nervous system, including the effect on neuronal excitability and on thermoregulatory processes. In addition, the nasal spray format makes it possible to conduct methodological research into the intranasal route of administration itself — into the stability of the peptide in solution, kinetics and the comparison of different routes of administration in models.

One Peptides quality specification

One-Peptides supplies DSIP as a research material of analytically confirmed quality, with full documentation accompanying each batch.

• HPLC purity ≥98% — each batch is analysed by high-performance liquid chromatography, which makes it possible to confirm the high degree of purity of the peptide.
• Identity confirmation by MS — mass spectrometry serves to verify the molecular mass and the identity of the sequence, which is a binding criterion for the identification of the peptide.
• Certificate of analysis (COA) for each batch — a certificate documenting the results of the analytical tests is enclosed with each batch.
• Cold chain 2–8°C — the material is stored and transported under refrigerated conditions, which helps to preserve its integrity.
• Batch traceability — the batch number makes it possible to link a specific package with the analytical documentation and the full history of its origin.

This scope of quality control allows research teams to work with material of known and documented characteristics, which is a precondition for the reproducibility of results in laboratory work.

Safety and limitations

The data on DSIP are limited, which should be emphasised as the fundamental context of any assessment of this peptide. Most of the available literature comes from early research conducted in the 1970s and 1980s and from preclinical work, while the contemporary, rigorous literature is relatively sparse.

In animal models, DSIP was generally described as a well-tolerated peptide, without clear signals of toxicity within the range of the experimental conditions analysed. Far-reaching conclusions should not, however, be drawn from this — the absence of documented warning signals in a limited number of studies is not equivalent to a confirmed safety profile.

The most important limitation remains the lack of long-term data on humans. There is no reliable body of clinical research that would allow the profile of this peptide in humans to be characterised, including under intranasal administration. For this reason DSIP remains a material of an exclusively research character, and any observations regarding its action should be referred to the experimental context in which they were obtained. Work with the reagent should be carried out in accordance with the principles of good laboratory practice and the appropriate safety procedures.

Regulatory status and WADA

DSIP is classified as a reagent for scientific research (Research Use Only) and is offered in this capacity. The peptide holds no authorisation as a medicinal product in the European Union or in other jurisdictions, nor is it authorised as a dietary supplement or medical device. This means that it is not subject to the marketing authorisation procedures appropriate to medicines and may not be presented as an agent with an established therapeutic action.

With regard to anti-doping regulations, according to the available information DSIP does not appear by name on the list of prohibited substances and methods of the World Anti-Doping Agency (WADA). The regulatory status of a substance may, however, change, and the interpretation of prohibited lists can be complex. For this reason verification of the current status — both anti-doping and legal in a given jurisdiction — remains the responsibility of the researcher and the institution conducting the research. One-Peptides does not provide legal or regulatory advice.

Frequently asked questions

What is DSIP?
DSIP (Delta Sleep-Inducing Peptide) is an endogenous nonapeptide with the sequence WAGGDASGE and a mass of approximately 848 Da, originally isolated from the blood of rabbits in the slow-wave sleep phase by the team of Monnier and Schoenenberger in the 1970s. In science it is studied as a potential neuromodulatory factor. One-Peptides offers it as a reagent for laboratory research (RUO), not as a product for use in humans.

What does the research say about sleep?
Early studies in animal models analysed the effect of DSIP on slow-wave sleep and the EEG recording, and some of them suggested an increase in the proportion of delta waves. These results, however, proved difficult to reproduce, and subsequent work produced an inconclusive picture. The literature emphasises the inconsistency of the data — which is why the role of DSIP in sleep physiology remains a research hypothesis, not an established fact.

What is the mechanism of action of DSIP?
The mechanism remains poorly understood. No receptor with which the peptide would specifically interact has been unambiguously identified to date, which constitutes the main limitation in the interpretation of results. Research has analysed the potential effect on the HPA stress axis and on neuromodulatory processes, yet without a known molecular target these observations require further verification.

Why the nasal spray format?
DSIP is a small peptide with central action, which makes it an interesting subject for research into intranasal administration and transport along the nose–brain axis. The nasal spray format was developed as a tool for such methodological research. Clinical data on this route of administration are, however, limited and come mainly from preclinical studies.

How to store the material to preserve stability?
DSIP in the form of a pre-dissolved solution requires storage under refrigerated conditions, in the range of 2–8°C (cold chain), with limited exposure to light and to repeated temperature fluctuations. Detailed recommendations on stability are provided in the certificate of analysis (COA) enclosed with each batch. The material should be handled in accordance with the rules applicable to research reagents.

Bibliography

1. Schoenenberger GA, Monnier M (1977). Characterization of a delta-electroencephalogram-(sleep)-inducing peptide
2. Monnier M et al. (1977). Delta sleep-inducing peptide (DSIP): EEG and motor activity in rabbits following intraventricular administration
3. Graf MV, Kastin AJ (1986). Delta-sleep-inducing peptide (DSIP): an update
4. Kovalzon VM, Strekalova TV (2006). Delta sleep-inducing peptide (DSIP): a still unresolved riddle

This material is a reagent intended solely for research purposes (Research Use Only). It is not a medicinal product, dietary supplement or medical device and may not be used in diagnostics or therapy in humans or animals. The information contained in the description is of a scientific and informational character, refers to data from the literature obtained under experimental conditions, and does not constitute medical, pharmaceutical or legal advice. All activities involving the reagent must be carried out by qualified personnel under laboratory conditions, in accordance with the applicable regulations. The purchaser bears full responsibility for the lawful use of the material.